O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. - Wikidata - wikimedia - TriplyDB

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

http://www.wikidata.org/entity/Q35001754

about

Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic origin Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors Targeting the mTOR signaling pathway in neuroendocrine tumors Summary of emerging personalized medicine in neuroendocrine tumors: are we on track?New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival.Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma.Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel.Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment.Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs Successful imatinib therapy for neuroendocrine carcinoma with activating Kit mutation: a case study Expression of O(6)-methylguanine DNA methyltransferase (MGMT) and its clinical significance in gastroenteropancreatic neuroendocrine neoplasm New treatment options for patients with advanced neuroendocrine tumors.ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary.Therapy for metastatic pancreatic neuroendocrine tumors.Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.Tumor-associated macrophages are a useful biomarker to predict recurrence after surgical resection of nonfunctional pancreatic neuroendocrine tumors.Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.Targeted therapy in advanced well-differentiated neuroendocrine tumors.O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)A new era for the systemic therapy of neuroendocrine tumors.First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors Update on management of midgut neuroendocrine tumors.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET)The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.

P2860

da0b1b9b904105853422be30d1271389a374a043

P248

Q21296729-078A4678-FDD9-4E9A-B88F-9A346F328FD2 Q26765289-F4866B37-945F-4B97-BF19-E2C1B69FC64C Q26852089-234BAF30-FF17-4C85-9FB4-C408A815CE38 Q28078610-AB0EF866-F61E-4E88-9DCD-5E4327B3F85E Q30364864-2B09298C-BEF1-4583-8DE2-0D31F486CF6B Q30412393-CB5F06BE-B3F4-4AEE-8150-1421BAC8E0A7 Q33402226-9B115952-2F89-44FC-884F-55CD78B46D53 Q33405625-3ECAB3BB-10BB-46B7-A81F-7A2288EF607A Q33436462-F5543CD4-3F54-43FC-B17A-861EDA71512A Q33781972-35370FFD-0CF8-4A86-9B05-FB5EFD04199E Q33782024-B184432C-A547-4EA6-AA6E-1A93F4FF992B Q33840177-FAB5AD78-737F-4F64-ADAA-CF626613F6F2 Q33914197-764DF5AC-C2B1-4FA9-B8B8-9692BACBE439 Q33948026-574F1683-10E5-48B7-A73F-6124C17833D2 Q33957571-8B1A6643-B1F5-44B7-ABE2-35D60FD65B92 Q34029197-3A0D7AE4-3EF7-4AAC-9933-3E6C318B157E Q34173336-81B52618-7FEB-435E-ADB2-90BC3F129EC4 Q34248487-C7566C25-0A48-4E64-B921-EF212007BD90 Q34357869-83999852-F7A4-4774-9DAD-71BC44799DA4 Q34743520-410474DE-5C4C-42A3-83A5-7680C1C21CD1 Q35001777-DD1A4412-CA2B-4714-8841-A2C96EB13943 Q35020652-6E92B759-CC96-40AF-903E-DB235388E923 Q35034000-8C389226-FF4C-44A5-987D-E9ABD0F00B3B Q35081993-A9B85CEA-626C-49B9-89B3-7FE4696C311D Q35128224-94B7DD80-406C-4986-BDDA-DDFC97128124 Q35563828-7E0BFF97-DAD5-4063-B464-67C5961A9090 Q35584497-112F990F-CE74-41A2-BA13-31BFCBB6D770 Q35677887-B05836C3-75BC-4659-8CE0-9358662C1A33 Q35760798-6E4AC883-5693-4076-9645-17633A43516A Q35863865-3C90F1C2-FF7D-4811-B19F-F29B4F313E5A Q36335402-9E28EDE6-156E-473A-BB4A-44C77879F99A Q36673960-41D5BBB1-7E6E-4B3E-8734-BC175F89E8E9 Q36790050-C0B74D6F-7091-4A7C-8788-F56987B8E4EE Q37025143-5A17B4DF-C2FD-422D-93E7-90A30C297D8C Q37125550-150A2715-0970-4C81-9EBA-76D24E398B97 Q37295241-636AF756-699E-48EE-844A-3D99366B4A1D Q37372483-234DC3F2-EF7D-4930-8022-8C1F3443E2F6 Q37468838-589B739C-4002-413D-93C8-912F85EFCA93 Q37594074-72C175E6-F346-47DD-9E89-FE5895D3FC04 Q37640526-E5F8328A-35D8-4590-A97B-B7F43B328AFF

P2860

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

http://www.wikidata.org/entity/Q35001754

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

O6-methylguanine DNA methyltra ...... ts with neuroendocrine tumors.

@ast

O6-methylguanine DNA methyltra ...... ts with neuroendocrine tumors.

@en

type

label

O6-methylguanine DNA methyltra ...... ts with neuroendocrine tumors.

@ast

O6-methylguanine DNA methyltra ...... ts with neuroendocrine tumors.

@en

prefLabel

O6-methylguanine DNA methyltra ...... ts with neuroendocrine tumors.

@ast

O6-methylguanine DNA methyltra ...... ts with neuroendocrine tumors.

@en

P1433

Q35001754-45D0485F-595E-4929-9B0D-DF083361B7F3

P1476

Q35001754-1CDA6DDD-D9BC-48CB-9421-75DAF3663ED3

P2093

Q35001754-18991B8F-55F3-4623-B99E-3E2723B1FDA2

Q35001754-1E18294D-7E89-46A9-85CC-D1F47815461F

Q35001754-8EA3435E-C807-468A-B6CB-EB2829EF236D

Q35001754-9DA1EDFA-6746-4ABC-B036-DDB8A13FFF6A

Q35001754-B1918918-A9CF-4E32-9F48-FF7AA20F0ACF

Q35001754-B2BE87C8-4771-4EDC-91A7-9E01341EBF1C

Q35001754-B6177655-BEFE-4E2A-9405-B85FFC8CD5E2

Q35001754-DC32CD16-49BF-4E35-BB79-C8176D814277

Q35001754-F03CC72D-1FA8-4C10-9B5B-4B07C6ED0EA0

P2860

Q35001754-14D90EDC-D3E8-4296-A3E2-83CF2BD7E1A2

Q35001754-193E0FBA-B92A-47E3-B098-A31DAD07CF00

Q35001754-2A960E4E-7AE2-45D5-ABF5-43065638D47F

Q35001754-2FF4F723-3C91-4ED5-9346-561C07D28004

Q35001754-31B9E60C-8FCF-4F3A-9251-B1D7827E0A0B

Q35001754-363DDB56-54C3-4CE4-AE48-6B711F5B1259

Q35001754-375DCDBA-0BF0-4939-90FD-2767DD24CFB9

Q35001754-41DEDE9B-99FC-4906-B3D2-146B4A24F43F

Q35001754-4233CA0F-6476-4FF7-83CD-654547CB91CD

Q35001754-57619E54-61A6-4069-A235-685379A55CD0

P304

Q35001754-406281BC-3749-4D3C-A26B-9460DD3C18A0

P31

Q35001754-47FC2ADC-EFB0-4656-9099-C88E6F7E4276

P356

Q35001754-C1535DE0-0D12-48CC-9043-3CBCD061914F

P407

Q35001754-B2C845DD-7672-441B-BA7D-7D204CA8173A

P433

Q35001754-A220CC7E-7B58-42FA-A759-D6487F5D1364

P478

Q35001754-784568CF-FB77-400B-93DB-B77D80B23DB0

P50

Q35001754-05E81CBB-92FE-41C4-BAFE-1570B193E2CC

Q35001754-A58C41F5-3B8F-4607-8FEC-056B5F0453B2

P577

Q35001754-D8888FA8-6A30-4B87-8F43-8FD76F89B60B

P698

Q35001754-78D16CCD-7ECB-42FA-B297-841A888F5A94

P932

Q35001754-4571C087-F3DF-4E19-BB7E-8476395F5AB6

P356

1078-0432.CCR-08-1476

P1433

Clinical Cancer Research

P1476

O6-methylguanine DNA methyltra ...... ts with neuroendocrine tumors.

@en

P2093

Christine Frauenhoffer

http://www.w3.org/2001/XMLSchema#string

David P Ryan

http://www.w3.org/2001/XMLSchema#string

Jason L Hornick

http://www.w3.org/2001/XMLSchema#string

Jeffrey W Clark

http://www.w3.org/2001/XMLSchema#string

Keith Stuart

http://www.w3.org/2001/XMLSchema#string

Mark S Redston

http://www.w3.org/2001/XMLSchema#string

Matthew H Kulke

http://www.w3.org/2001/XMLSchema#string

Peter C Enzinger

http://www.w3.org/2001/XMLSchema#string

Susanne Hooshmand

http://www.w3.org/2001/XMLSchema#string

P2860

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

Clinical relevance of MGMT in the treatment of cancer.

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.

Targeted modulation of MGMT: clinical implications.

O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.

P304

338-345

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-1476

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Charles S. Fuchs

Jeffrey A Meyerhardt

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19118063

http://www.w3.org/2001/XMLSchema#string

P932

3100724

http://www.w3.org/2001/XMLSchema#string